How actual is the treatment with antiandrogen alone in patients with polycystic ovary syndrome?

  title={How actual is the treatment with antiandrogen alone in patients with polycystic ovary syndrome?},
  author={E. Diamanti‐Kandarakis},
  journal={Journal of Endocrinological Investigation},
4 Citations
CHAPTER 20 – Polycystic Ovary Syndrome and Hyperandrogenic States
Abstract Polycystic ovary syndrome is the most common endocrinopathy of reproductive-aged women. Major clinical manifestations include hirsutism and irregular menstrual bleeding as a result ofExpand
Spironolactone in the treatment of polycystic ovary syndrome: Effects on clinical features, insulin sensitivity and lipid profile
The data show that long-term treatment with spironolactone exerts no negative effects on lipoprotein profile and glucose metabolism; more relevant beneficial effects on glucose and lipid metabolism were observed when the antiandrogen was associated with weight loss in overweight PCOS women. Expand


Hormonal effects of flutamide in young women with polycystic ovary syndrome.
This finding supports the hypothesis that flutamide reduces androgen synthesis through restoration of ovulation, although a direct block of the steroidogenic enzymes of androgen biosynthesis in ovarian thecal cells cannot be excluded. Expand
The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome.
It is demonstrated for the first time that treatment with the pure antiandrogen, flutamide, may improve the lipid profile and that this effect may be due to direct inhibition of androgenic actions. Expand
Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome.
It is confirmed that metformin treatment can lead to improvements in insulin resistance and ovarian hyperandrogenism. Expand
Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.
  • A. Dunaif
  • Biology, Medicine
  • Endocrine reviews
  • 1997
Since PCOS usually has a menarchal age of onset, this makes it a particularly appropriate disorder in which to examine the ontogeny of defects in carbohydrate metabolism and for ascertaining large three-generation kindreds for positional cloning studies to identify NIDDM genes. Expand
The Polycystic Ovary Syndrome Pathogenesis, Metabolic Implications, and Therapeutic Approach
Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies and is probably the most frequent cause of infertility affecting women of reproductive age.'S2 It is a condition of unknownExpand
New perspectives in polycystic ovary syndrome
The current state of the field with respect to the pathogenesis of PCOS and the insulin resistance associated with it is reviewed. Expand
The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women.
Antiandrogen treatment partially reversed the peripheral insulin resistance associated with hyperandrogenism regardless of which antiandrogen was used, suggesting that in women, androgen excess per se contributes to impairment of insulin action. Expand
Androgens and Therapeutic Aspects of Antiandrogens in Women
Antiandrogens provide a logical and clinically effective pharmacotherapy of hyperandrogenic disorders and both steriodal and nonsteroidal antiandrogens may cause significant side effects, largely because of their interactions not only with androgen receptors, but also with other receptors and various enzymatic activities. Expand
Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome.
In both lean and obese PCO women, treatment with flutamide for 1 or 3 months markedly improved the clinical and biochemical androgenic features, but did not significantly influence the overall insulin sensitivity, indicating that PCO and obesity exert synergistic effects on insulin resistance. Expand
Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial.
The present data obtained in a randomized prospective study clearly demonstrate that the pure antiandrogen flutamide is superior to spironolactone in the treatment of female hirsutism and its related androgen-dependent symptoms and signs in women. Expand